Skip to content

The efficacy and mechanism of deep brain stimulation in the treatment of refractory depression

The efficacy and mechanism of deep brain stimulation in the treatment of refractory depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114614
Enrollment
Unknown
Registered
2025-12-15
Start date
2025-12-31
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depression Disorder

Interventions

Group A:Deep brain stimulation implantation. The first month is the start-up period, and the second month is the shutdown period.
Group B:Deep brain stimulation implantation. The first month is the shutdown period, and the second month is the start-up period.

Sponsors

the Second Affiliated Hospital of Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1)18-70 years old, gender not limited; 2) Conform to the diagnosis Of major depressive disorder by a psychiatrist as stipulated in the Diagnostic And Statistical Manual Of Mental Disorders, 4th Ed (DSM-V) of the United States; 3) Mental examinations were conducted by two trained psychiatrists and diagnoses were made in accordance with DSM-V, with consistent diagnoses. 4) A history of depression lasting at least 24 months, for those with a Hamilton Depression Scale (HDRS-17) score reduction rate of no more than 20% after adequate and full-course treatment with two or more antidepressants (including MECT); 5) The score of the 17 items of the HDRS-17 scale at the initial screening is >= 20; 6) The score of the Global Assessment Function (GAF) is <= 50; 7) The patient or their legal guardian must fully understand the therapy and agree to sign the informed consent form before being enrolled in the group.

Exclusion criteria

Exclusion criteria: 1) Patients with severe or unstable internal diseases such as heart, liver, kidney, endocrine, and hematological disorders, as well as those with comorbidities accompanied by psychotic symptoms, including personality disorders diagnosed through medical history, inquiry, and clinical examination; 2) There is a history of drug abuse within 12 months; Those with a history of epilepsy and those with febrile convulsions in childhood; 3) Patients who have attempted suicide within the past six months or more than twice within the past two years; 4) Women who are breastfeeding or pregnant, as well as patients who are pregnant or planning to become pregnant during clinical research; 5) Patients with contraindications to MRI scans (such as cardiac pacemakers, metals in the body, severe claustrophobia), and abnormal brain MRI; 6) Contraindications for DBS surgery and chronic stimulation.

Design outcomes

Secondary

MeasureTime frame
Montgomery-Asberg Depression Rating Scale;Quick Inventory of Depressive Symptomatology;multi-lingual Hypomania Check List;Hamilton Anxiety Scale;HCL-32;Clinical Global Impression;Global Assessment of Function;36-Item Short Form Health Survey;BIS-11;Frontal Assessment Battery;Pittsburgh sleep quality index;

Primary

MeasureTime frame
Hamilton Rating Scale for Depression;

Countries

China

Contacts

Public ContactLiangwen Zhang

the Second Affiliated Hospital of Shandong First Medical University

13793182116@163.com+86 185 6008 5716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026